|
1
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ljungberg B, Campbell SC, Choi HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
National Comprehensive Cancer Network
(NCCN): NCCN Clinical Practice Guidelines in Oncology: Kidney
Cancer. Version 1.2017. www.nccn.org. Accessed February 6,
2017.
|
|
9
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A; ESMO
Guidelines Committee: Renal cell carcinoma: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
27(Suppl 5): v58–v68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Christensen JG: A preclinical review of
sunitinib, a multitargeted receptor tyrosine kinase inhibitor with
anti-angiogenic and anti-tumour activities. Ann Oncol. 18(Suppl
10): x3–10. 2007. View Article : Google Scholar
|
|
11
|
Faivre S, Demetri G, Sargent W and Raymond
E: Molecular basis for sunitinib efficacy and future clinical
development. Nat Rev Durg Discov. 6:734–745. 2007. View Article : Google Scholar
|
|
12
|
Oudard S and Elaidi RT: Sequential therapy
with targeted agents in patients with advanced renal cell
carcinoma: Optimizing patient benefit. Cancer Treat Rev.
38:981–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Molina AM, Lin X, Korytowsky B, Matczak E,
Lechuga MJ, Wiltshire R and Motzer RJ: Sunitinib objective response
in metastatic renal cell carcinoma: Analysis of 1059 patients
treated on clinical trials. Eur J Cancer. 50:351–358. 2014.
View Article : Google Scholar
|
|
14
|
Zhao T, Bao Y, Gan X, Wang J, Chen Q, Dai
Z, Liu B, Wang A, Sun S, Yang F and Wang L: DNA
methylation-regulated QPCT promotes sunitinib resistance by
increasing HRAS stability in renal cell carcinoma. Theranostics.
9:6175–6190. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kehlen A, Haegele M, Menge K, Gans K,
Immel UD, Hoang-Vu C, Klonisch T and Demuth HU: Role of glutaminyl
cyclases in thyroid carcinomas. Endocr Relat Cancer. 20:79–90.
2013. View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Yu X, Petritis B and LaBaer J: Advancing
translational research with next-generation protein microarrays.
Proteomics. 16:1238–1250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen SM, Ji Y, Zhang C, Dong SS, Yang S,
Xiong Z, Ge MK, Yu Y, Xia L, Guo M, et al: Nuclear PTEN safeguards
pre-mRNA splicing to link Golgi apparatus for its tumor suppressive
role. Nat Commun. 9:23922018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Z, Ai X, Hu H, Wang S, Wang Y, Kang F,
Ouyang C and Zhu J: Hematopoietic-substrate-1 associated protein
X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and
angiogenesis through Akt. Cancer Biol Ther. 20:1223–1233. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang T, Yao Y, Wang J, Li Y, He P,
Pasupuleti V, Hu Z, Jia X, Song Q, Tian XL, et al:
Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1
inhibits developmental and pathological angiogenesis by
inactivating PI3K and AKT and disrupts vascular integrity by
activating VE-cadherin. Hum Mol Genet. 25:5094–5110.
2016.PubMed/NCBI
|
|
21
|
Zhang L, Yang N, Katsaros D, Huang W, Park
JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W,
Rubin SC and Coukos G: The oncogene phosphatidylinositol 3′-kinase
catalytic subunit alpha promotes angiogenesis via vascular
endothelial growth factor in ovarian carcinoma. Cancer Res.
63:4225–4231. 2003.PubMed/NCBI
|
|
22
|
Murillo MM, Zelenay S, Nye E, Castellano
E, Lassailly F, Stamp G and Downward J: RAS interaction with PI3K
p110α is required for tumor-induced angiogenesis. J Clin Invest.
124:3601–3611. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Joosten SC, Hamming L, Soetekouw PM, Aarts
MJ, Veeck J, van Engeland M and Tjan-Heijnen VC: Resistance to
sunitinib in renal cell carcinoma: From molecular mechanisms to
predictive markers and future perspectives. Biochim Biophys Acta.
1855:1–16. 2015.
|
|
24
|
Fernando NT, Koch M, Rothrock C, Gollogly
LK, D'Amore PA, Ryeom S and Yoon SS: Tumor Escape from endogenous,
extracellular matrix-associated angiogenesis inhibitors by
up-regulation of multiple proangiogenic factors. Clin Cancer Res.
14:1529–1539. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oudard S, Geoffrois L, Guillot A, Chevreau
C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre
B, et al: Clinical activity of sunitinib rechallenge in metastatic
renal cell carcinoma-Results of the REchallenge with SUnitinib in
MEtastatic RCC (RESUME) Study. Eur J Cancer. 62:28–35. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jarzab B, Wiench M, Fujarewicz K, Simek K,
Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E,
Lange D, et al: Gene expression profile of papillary thyroid
cancer: Sources of variability and diagnostic implications. Cancer
Res. 65:1587–1597. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fluge Ø, Bruland O, Akslen LA, Lillehaug
JR and Varhaug JE: Gene expression in poorly differentiated
papillary thyroid carcinomas. Thyroid. 16:161–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Griffith OL, Melck A, Jones SJ and Wiseman
SM: Meta-analysis and meta-review of thyroid cancer gene expression
profiling studies identifies important diagnostic biomarkers. J
Clin Oncol. 24:5043–5051. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gillis JS: Microarray evidence of
glutaminyl cyclase gene expression in melanoma: Implications for
tumor antigen specific immunotherapy. J Transl Med. 4:272006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oh S, Oh C and Yoo KH: Functional roles of
CTCF in breast cancer. BMB Rep. 50:445–453. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aitken SJ, Ibarra-Soria X, Kentepozidou E,
Flicek P, Feig C, Marioni JC and Odom DT: CTCF maintains regulatory
homeostasis of cancer pathways. Genome Biol. 19:1062018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bailey CG, Metierre C, Feng Y, Baidya K,
Filippova GN, Loukinov DI, Lobanenkov VV, Semaan C and Rasko JE:
CTCF expression is essential for somatic cell viability and
protection against cancer. Int J Mol Sci. 19:38322018. View Article : Google Scholar
|
|
34
|
Lee JY, Mustafa M, Kim CY and Kim MH:
Depletion of CTCF in breast cancer cells selectively induces cancer
cell death via p53. J Cancer. 8:2124–2131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ren G, Jin W, Cui K, Rodrigez J, Hu G,
Zhang Z, Larson DR and Zhao K: CTCF-mediated enhancer-promoter
interaction is a critical regulator of cell-to-cell variation of
gene expression. Mol Cell. 67:1049–1058.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Höflmayer D, Steinhoff A, Hube-Magg C,
Kluth M, Simon R, Burandt E, Tsourlakis MC, Minner S, Sauter G,
Büscheck F, et al: Expression of CCCTC-binding factor (CTCF) is
linked to poor prognosis in prostate cancer. Mol Oncol. 14:129–138.
2020. View Article : Google Scholar
|
|
37
|
Kemp CJ, Moore JM, Moser R, Bernard B,
Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, et
al: CTCF haploinsufficiency destabilizes DNA methylation and
predisposes to cancer. Cell Rep. 7:1020–1029. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chan CS and Song JS: CCCTC-binding factor
confines the distal action of estrogen receptor. Cancer Res.
68:9041–9049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hosseini S, Behjati F, Rahimi M, Taheri N,
Khoram Khorshid H, Aghakhani Moghaddam F, Ghasemi S, Karimlou M,
Sirati F and Keyhani E: Relationship between PIK3CA amplification
and P110α and CD34 tissue expression as angiogenesis markers in
Iranian women with sporadic breast cancer. Iran J Pathol.
13:447–453. 2018.
|
|
40
|
Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL,
Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, et al: Genes involved
in angiogenesis and mTOR pathways are frequently mutated in Asian
patients with pancreatic neuroendocrine tumors. Int J Biol Sci.
12:1523–1532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Riquelme I, Tapia O, Espinoza JA, Leal P,
Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC:
The Gene Expression status of the PI3K/AKT/mTOR pathway in gastric
cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
du Rusquec P, Blonz C, Frenel JS and
Campone M: Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor
positive HER2 negative advanced breast cancer. Ther Adv Med Oncol.
12:1758835920940932020. View Article : Google Scholar
|
|
43
|
Sasore T and Kennedy B: Deciphering
combinations of PI3K/AKT/mTOR pathway drugs augmenting
Anti-angiogenic efficacy in vivo. PLoS One. 9:e1052802013.
View Article : Google Scholar
|
|
44
|
Bader AG, Kang S and Vogt PK:
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc
Natl Acad Sci USA. 103:1475–1479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
De Santis MC, Gulluni F, Campa CC, Martini
M and Hirsch E: Targeting PI3K signaling in cancer: Challenges and
advances. Biochim Biophys Acta Rev Cancer. 1871:361–366. 2019.
View Article : Google Scholar : PubMed/NCBI
|
